SPEVIGO conc perf 450 mg/7.5ml 2 flac 7.5 ml
7680686250017
CH-68625
L04AC22
07.15.0.
Reimbursement limitations:
SPEVIGO
Traitement des poussées de psoriasis pustuleux généralisé (PPG) en monothérapie chez l’adulte.
L’établissement du diagnostic …
1 / 3
google
Details
- Product number
- 6862501
- CPT
- -
- Packaging group
- 2
- Unit
- Durchstechflasche(n)
- Composition
- spesolimabum 450 mg, natrii acetas trihydricus, acidum aceticum glaciale, saccharum 386 mg, arginini hydrochloridum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 7.5 ml, natrium 6.8 mg.
Articles (1)
Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
2
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
450.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
386.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
6.8 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 16701.95
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/01/2025
Authorization holder
Boehringer Ingelheim (Schweiz) GmbH
4057 Basel
Authorization information
- Swissmedic authorization number
- 68625
- Drug name
- Spevigo, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L04AC22
- Authorization status
- B
- Dispensation category
- A
- First authorization
- 09/08/2023
- Authorization expiration date
- 21/05/2026
- IT number
- 07.15.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- SPEVIGO conc perf 450 mg/7.5ml 2 flac 7.5 ml
- Description (DE)
- SPEVIGO Inf Konz 450 mg/7.5ml 2 Durchstf 7.5 ml
- Market launch
- 09/08/2023
- Narcotic (BTM)
- No